This company listing is no longer active
Salud financiera de hoja de balance de Clover Biopharmaceuticals
Salud financiera controles de criterios 3/6
Clover Biopharmaceuticals has a total shareholder equity of CN¥28.6M and total debt of CN¥410.0M, which brings its debt-to-equity ratio to 1435.8%. Its total assets and total liabilities are CN¥3.1B and CN¥3.1B respectively.
Información clave
1,435.8%
Ratio deuda-patrimonio
CN¥409.95m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | CN¥1.30b |
| Patrimonio | CN¥28.55m |
| Total pasivo | CN¥3.05b |
| Activos totales | CN¥3.08b |
Actualizaciones recientes sobre salud financiera
No hay actualizaciones
Recent updates
Análisis de la situación financiera
Pasivos a corto plazo: 2197's short term assets (CN¥2.8B) exceed its short term liabilities (CN¥2.4B).
Pasivo a largo plazo: 2197's short term assets (CN¥2.8B) exceed its long term liabilities (CN¥683.2M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: 2197 has more cash than its total debt.
Reducción de la deuda: Insufficient data to determine if 2197's debt to equity ratio has reduced over the past 5 years.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: 2197 has less than a year of cash runway based on its current free cash flow.
Pronóstico de cash runway: 2197 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 66.7% each year